Systematic screening for fragile X syndrome in a cohort of 574 mentally retarded children. 1997

B Gérard, and M F Le Heuzey, and G Brunie, and P Lewine, and M C Saiag, and V Cacheux, and F Da Silva, and M Dugas, and M C Mouren-Simeoni, and J Elion, and B Grandchamp
Laboratoire de Biochimie Génétique, Hôpital Robert Debré, Paris, France.

In this study, we evaluated the prevalence of the fragile X syndrome in a cohort of 574 mentally retarded children. The only inclusion criterion was the diagnosis of mental retardation according to the DSM-IIIR classification. We used a PCR-based strategy for the diagnosis of fragile X syndrome to facilitate systematic screening. This diagnostic scheme is based on an initial PCR to eliminate most fragile X-negative patients followed by Southern blotting for fragile X syndrome diagnosis. Altogether, 403 boys and 171 girls were tested. The prevalence of this genetic disorder was 1.9% (11/574) in the whole cohort and 2.5% (10/403) in boys. Only one case of fragile X syndrome was detected among the 171 girls tested (0.6%). Clinical examination, especially in the youngest children, was often unremarkable, and the only reason for suspecting fragile X syndrome was the presence of mental retardation. Thus, a systematic screening for the fragile X syndrome in mentally retarded children seems justified because of the importance of a precise diagnosis in genetic counseling.

UI MeSH Term Description Entries
D008297 Male Males
D008607 Intellectual Disability Subnormal intellectual functioning which originates during the developmental period. This has multiple potential etiologies, including genetic defects and perinatal insults. Intelligence quotient (IQ) scores are commonly used to determine whether an individual has an intellectual disability. IQ scores between 70 and 79 are in the borderline range. Scores below 67 are in the disabled range. (from Joynt, Clinical Neurology, 1992, Ch55, p28) Disability, Intellectual,Idiocy,Mental Retardation,Retardation, Mental,Deficiency, Mental,Intellectual Development Disorder,Mental Deficiency,Mental Retardation, Psychosocial,Deficiencies, Mental,Development Disorder, Intellectual,Development Disorders, Intellectual,Disabilities, Intellectual,Disorder, Intellectual Development,Disorders, Intellectual Development,Intellectual Development Disorders,Intellectual Disabilities,Mental Deficiencies,Mental Retardations, Psychosocial,Psychosocial Mental Retardation,Psychosocial Mental Retardations,Retardation, Psychosocial Mental,Retardations, Psychosocial Mental
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D005600 Fragile X Syndrome A condition characterized genotypically by mutation of the distal end of the long arm of the X chromosome (at gene loci FRAXA or FRAXE) and phenotypically by cognitive impairment, hyperactivity, SEIZURES, language delay, and enlargement of the ears, head, and testes. INTELLECTUAL DISABILITY occurs in nearly all males and roughly 50% of females with the full mutation of FRAXA. (From Menkes, Textbook of Child Neurology, 5th ed, p226) FRAXA Syndrome,FRAXE Syndrome,Martin-Bell Syndrome,Fra(X) Syndrome,Fragile X Mental Retardation Syndrome,Fragile X-F Mental Retardation Syndrome,Mar (X) Syndrome,Marker X Syndrome,Mental Retardation, X-Linked, Associated With Fragile Site Fraxe,Mental Retardation, X-Linked, Associated With Marxq28,X-Linked Mental Retardation and Macroorchidism,FRAXA Syndromes,FRAXE Syndromes,Fragile X Syndromes,Marker X Syndromes,Martin Bell Syndrome,Syndrome, FRAXA,Syndrome, FRAXE,Syndrome, Fragile X,Syndrome, Marker X,Syndrome, Martin-Bell,Syndromes, FRAXA,Syndromes, FRAXE,Syndromes, Fragile X,Syndromes, Marker X,X Linked Mental Retardation and Macroorchidism
D005820 Genetic Testing Detection of a MUTATION; GENOTYPE; KARYOTYPE; or specific ALLELES associated with genetic traits, heritable diseases, or predisposition to a disease, or that may lead to the disease in descendants. It includes prenatal genetic testing. Genetic Predisposition Testing,Genetic Screening,Predictive Genetic Testing,Predictive Testing, Genetic,Testing, Genetic Predisposition,Genetic Predictive Testing,Genetic Screenings,Genetic Testing, Predictive,Predisposition Testing, Genetic,Screening, Genetic,Screenings, Genetic,Testing, Genetic,Testing, Genetic Predictive,Testing, Predictive Genetic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D015995 Prevalence The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time. Period Prevalence,Point Prevalence,Period Prevalences,Point Prevalences,Prevalence, Period,Prevalence, Point,Prevalences

Related Publications

B Gérard, and M F Le Heuzey, and G Brunie, and P Lewine, and M C Saiag, and V Cacheux, and F Da Silva, and M Dugas, and M C Mouren-Simeoni, and J Elion, and B Grandchamp
January 2002, Acta paediatrica (Oslo, Norway : 1992),
B Gérard, and M F Le Heuzey, and G Brunie, and P Lewine, and M C Saiag, and V Cacheux, and F Da Silva, and M Dugas, and M C Mouren-Simeoni, and J Elion, and B Grandchamp
January 1992, TSitologiia i genetika,
B Gérard, and M F Le Heuzey, and G Brunie, and P Lewine, and M C Saiag, and V Cacheux, and F Da Silva, and M Dugas, and M C Mouren-Simeoni, and J Elion, and B Grandchamp
May 1991, Clinical genetics,
B Gérard, and M F Le Heuzey, and G Brunie, and P Lewine, and M C Saiag, and V Cacheux, and F Da Silva, and M Dugas, and M C Mouren-Simeoni, and J Elion, and B Grandchamp
June 1999, Journal of medical genetics,
B Gérard, and M F Le Heuzey, and G Brunie, and P Lewine, and M C Saiag, and V Cacheux, and F Da Silva, and M Dugas, and M C Mouren-Simeoni, and J Elion, and B Grandchamp
June 1996, Human genetics,
B Gérard, and M F Le Heuzey, and G Brunie, and P Lewine, and M C Saiag, and V Cacheux, and F Da Silva, and M Dugas, and M C Mouren-Simeoni, and J Elion, and B Grandchamp
November 2000, American journal of medical genetics,
B Gérard, and M F Le Heuzey, and G Brunie, and P Lewine, and M C Saiag, and V Cacheux, and F Da Silva, and M Dugas, and M C Mouren-Simeoni, and J Elion, and B Grandchamp
January 2000, Annals of Saudi medicine,
B Gérard, and M F Le Heuzey, and G Brunie, and P Lewine, and M C Saiag, and V Cacheux, and F Da Silva, and M Dugas, and M C Mouren-Simeoni, and J Elion, and B Grandchamp
June 2001, Journal of Korean medical science,
B Gérard, and M F Le Heuzey, and G Brunie, and P Lewine, and M C Saiag, and V Cacheux, and F Da Silva, and M Dugas, and M C Mouren-Simeoni, and J Elion, and B Grandchamp
July 1999, Clinical genetics,
B Gérard, and M F Le Heuzey, and G Brunie, and P Lewine, and M C Saiag, and V Cacheux, and F Da Silva, and M Dugas, and M C Mouren-Simeoni, and J Elion, and B Grandchamp
July 1994, American journal of medical genetics,
Copied contents to your clipboard!